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Background/aim: This study aimed to evaluate the diameter and flow changes in the circle of Willis and side branches following the use
of FDSs extending from the middle cerebral artery (MCA) to the internal carotid artery (ICA) for the treatment of aneurysms in the
terminal segment of ICA, and the clinical results.
Material and method: This study was conducted in a single center between January 2012 and April 2018 in patients with the anterior
choroidal artery (AChoA), the posterior communicating artery (PComA), and the ICA terminal segment aneurysms treated with the
FDSs. The changes in aneurysm size, arterial structures covered by the FDSs, and changes in the diameter and flow in arteries forming
the circle of Willis were retrospectively analyzed.
Results: Fourteen patients with a total of 25 aneurysms treated with FDSs extending from MCA to ICA were evaluated. The mean
aneurysm fundus size was 5.14 mm (range 1.5–22 mm). Before treatment, the anterior communicating artery (AComA) was patent
in all patients. Implanted FDSs covered the anterior cerebral artery (ACA) and AChoA in all patients (100%), nonhypoplasic PComA
in two patients (14.28%), and the ophthalmic artery in nine (64.3%). The mean follow-up time was 36.78 ± 22.44 months. In followup, there was a decrease in the mean ipsilateral ACA A1 segment diameter from 1.99 ± 0.58 cm to 1.81 ± 0.31 cm (p = 0.01). The
mean contralateral A1 segment diameter increased from 1.66 ± 0.48 cm to 1.93 ± 0.42 cm (p = 0.004). All aneurysms were totally
occluded.
Conclusion: If the AComA is patent, ipsilateral anterior circulation can be compensated through modifications in the contralateral
ACA A1 segment in patients with ICA terminal segment aneurysms treated with FDSs extended from MCA to ICA and covering ACA.
Although covering the anterior choroidal and lenticulostriate arteries by FDSs, ischemic complications may not occur frequently. Thus,
this effective therapy can be applied more safely.
Key words: Flow-diverting stents, circle of Willis, intracranial aneurysm

1. Introduction
Flow diverting stents (FDSs) alone or in combination
with coil embolization are very important development
for the treatment of technically challenging, wide-neck,
and previously treated residual/recurrent aneurysms
[1–9]. Most studies on FDSs have focused on whether
the aneurysm can be successfully occluded. However, in
recent years, one of the topics that have been increasingly
emphasized in research is ischemic complications that
may develop due to the side branches and perforating
arteries covered by FDSs [9–11]. Ischemic complications
that may arise with the use of FDSs, which have a smaller
pore structure than conventional stents, especially in cases
where they cover perforating, and major branches cause

concerns. Animal experiments conducted to clarify this
issue have used flow dynamics and advanced diagnostic
methods and demonstrated that the covered branches
could undergo modification when compensated by
collateral arteries. There would be no significant diameter
difference when collateral arteries are not functional [12–
14].
This study aimed to investigate the diameter and flow
changes in the arteries included in the circle of Willis
following the use of FDSs extending from the middle
cerebral artery (MCA) to the internal carotid artery
(ICA) for the treatment of aneurysms in the ICA terminal
segment and to evaluate the presence of clinical and
radiological ischemic findings.
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2. Material and methods
2.1. Study design and patient selection
This single-center, retrospective study was conducted
between January 2012 and April 2018. Before the procedure,
informed consent was obtained from the patients, and
approval was received from the local ethics committee.
Fourteen patients with 25 aneurysms of the ICA terminal
segment, AChoA, and PComA, in which ACA was
treated by covering with FDS, were included in the study.
The inclusion criteria were having recurrent/residual
aneurysms detected during the follow-up of endovascular
or surgical treatment and/or having aneurysms considered
to have a high risk of complications according to the
assessment undertaken due to clinical and demographic
and undergoing the endovascular procedure in which
ACA was covered with the FDS. Arterial diameters and
changes were calculated on 2D images. All cases were
treated electively.
2.2. Medication
In all patients, 100 mg acetylsalicylic acid (ASA; Aspirin;
Bayer Healthcare, Germany) and 75 mg clopidogrel (Plavix;
Bristol-Myers Squibb/Sanofi Pharmaceuticals, NY, USA)
were started daily at least seven days before treatment. The
sensitivity of ASA and clopidogrel were evaluated with
VerifyNow (Accumetrics, San Diego, CA, USA) one or
two days before the treatment. According to the sensitivity
of the antiplatelets, if Aspirin sensitivity was under the
threshold, the dose was increased to 300 mg a day, and
if clopidogrel sensitivity was under 30%, clopidogrel was
replaced with ticlopidine 250 twice daily (Ticlocard; Kocak
Farma, Istanbul, Turkey), ticagrelor 90 mg twice daily
or prasugrel 10 mg daily was initiated in those without
contraindications. Dual antiplatelet treatment was applied
for at least six months. Subsequently, monotherapy was
continued indefinitely, preferably with ASA.
2.3. Technique
All treatments were performed under general anesthesia.
All procedures were performed by entering through the
right femoral artery. A long 6F introducer, a five or 6F
distal access guiding catheter, a 0.027-inch microcatheter,
and a 0.014-inch micro-guidewire were used in accordance
with the anatomy of ICA and the stent to be used. Six
different stents were used in the treatment: Pipeline flex
(Medtronic Covidien AG, Paris, France) (n = 2), Silk (Balt,
Montmorency, France) (n = 3), Derivo (Acandis) (n =
5), Surpass (Stryker Neuroendovascular, Kalamazoo, MI,
USA) (n = 2), two Pipeline Shield (Medtronic Covidien
AG, Paris, France), and Derivo2 (Acandis, Pforzheim,
Germany) (n = 1). Three Silk (Balt) stents were used in
one patient, and two Surpass (Stryker) stents were used in
another patient in the same session, while a single FDS was
used in the remaining 12 patients.
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3D rotational angiography and cone-beam CT (Artis
zee biplane; Siemens Healthineers, Erlangen, Germany)
were used to select the stent size. If the distance between
the aneurysm neck and the ICA bifurcation was 5mm or
less, the stent has been deployed starting from the MCA
M1 segment.
The aneurysm neck was covered with an FDS extending
to least five mm from the proximal and distal region of the
aneurysm neck. The shortest stent was chosen not to cover
many more arteries as far as possible.
At the beginning of the procedure, a bolus dose of 5000
IU IV heparin was administered. Then, an additional IV
1000 IU heparin was administered at each subsequent hour
to ensure the activated clotting time was two to three times
the baseline value. The patients were followed up clinically
in the intensive care unit for 24 h after the procedure.
During this period, heparin infusion was started at varying
doses (500–750 IU/h) according to the patients’ weight,
and antiplatelet treatments were continued.
2.4. Follow-up and statistical analysis
The first follow-up of all patients was undertaken by
digital subtraction angiography (DSA) in the third or sixth
month. Then, annual DSA follow-ups were conducted
to evaluate aneurysm occlusion and stent patency. MRI
was performed urgently in cases of symptoms suggesting
stent thrombosis after treatment. Although there were
no symptoms, all patients were evaluated with diffusionweighted MRI for occult ischemia postprocedure first
day. In one patient that did not want to have a DSA after
the sixth-month examination due to the total occlusion,
complete stent patency, and symptom relief, the maximum
follow-up period was limited to six months when
performing the statistical analysis. However, the follow-up
of this patient was continued with computed tomography
and magnetic resonance angiography.
During all follow-ups, the covered arteries and the
flow in the circle of Willis were evaluated on 2D images.
Additionally, the diameter of the ipsilateral posterior
cerebral artery (PCA) P1 segment was recorded. The
occlusion of aneurysms was assessed based on the
Raymond-Roy classification.
IBM SPSS Statistics version 20.0 package program was
used for the statistical analysis of the data. Categorical
measurements were summarized as numbers and
percentages, and numerical measurements as mean
and standard deviation (minimum-maximum where
necessary). The Wilcoxon signed-rank test compared two
dependent numerical measurements that did not show
normal distribution. The statistical significance level was
taken as 0.05 in all tests.
3. Results
A total of 25 aneurysms were identified: 18 in the ICA
terminal segment (72%), five in the AChoA orifice (20%),
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and two in the PComA orifice (8%) (Table 1). The mean size
of the aneurysm fundus was measured as approximately
5.14 mm (1.5–22 mm). The sample consisted of 11 female
(78.6%) patients and three male (21.4%). In the treatment
of aneurysms in all patients, at least one FDS was used. In
six (24%) of the 25 aneurysms, a combination of an FDS
and coil embolization was utilized. AComA was patent in
all cases, while ipsilateral PComA patency was detected in
two patients. In the remaining 12 patients, the ipsilateral
PComA was hypoplasic. After treatment, the FDSs were
seen to have covered AChoA and ACA in 14 patients,
PComA in two (14.28%), and the ophthalmic artery in
nine (64.3%) (Table 2, Figure 1).
The mean follow-up was 36.78 ± 22.44 months (range,
6–94 months). During the follow-up, it was determined
that there was a decrease in the mean diameter of the
ipsilateral ACA A1 segment from 1.99 ± 0.58 cm to 1.81
± 0.31 cm (p = 0.01). In contrast, the mean diameter of
the contralateral A1 segment increased from 1.66 ± 0.48
cm to 1.93 ± 0.42 cm (p = 0.004). For the ipsilateral ACA,
occlusion was seen in two patients (14.28%) (Figure 2 a-c),
while the remaining 12 patients (85.71%) presented with a
reduced diameter and in the flow on DSA. In contrast, on
the contralateral ACA A1 segment, there was an increase
in diameter and flow in 13 patients (92.85%). At the same
time, no significant change was noted in the diameter
or DSA flow in the remaining patient compared to the
pretreatment values.
In nine patients (64.28%), the FDS covered the
ophthalmic artery, and the mean diameter of the covered
arteries decreased from 0.66 ± 0.19 cm to 0.51 ± 0.33 cm
(p = 0.068). Ophthalmic artery occlusion developed in
two patients; however, no visual symptoms developed in
either case. Before the procedure, two of 14 patients had
ipsilateral PComA patency. In both cases, the artery was
covered with an FDS, and one was occluded after the
procedure. Both PComA cases were also nonfetal. The
mean diameter of the ipsilateral PCA P1 segment was
observed to have increased from 1.81 ± 0.31 cm to 1.86 ±
0.29 cm (p = 0.899).
Fourteen ACA and AChoA, nine ophthalmic arteries,
and two PComA were covered by FDSs (Table 2, Figure
1). AChoA was covered with a flow diverting stent in

all patients, but none developed occlusion in this artery.
In one patient, AChoA originated from the aneurysm
neck (Figure 3a). But there was no residual filling
in the aneurysm, although there was no decrease in
calibration due to remodeling in AChoA compared to the
preprocedural evaluation (Figure 3b). On the DSA that
was received immediately after the procedure, there was
no change in the flow form or diameter of the covered
arteries, except one. The details of this case that showed
changes were given in the periprocedural complication
section. Additionally, in one more patient, proximal
stenosis was detected at the 24th-month follow-up, and
this complication is discussed in the late complication
section.
In the 24th-hour control examination of the patients,
no finding suggesting early-stage clinical ischemia was
detected. Diffusion MRI was used to rule out silent
ischemia, and very small
foci of acute infarction were found in six patients
(42.85%) without any clinical findings. It was determined
that among the cases presenting silent ischemia, a single
FDS had been used in five (83.3%) and two FDSs in two
(16.7%). Silent ischemia was not detected in a case in
which three FDSs had been implanted. In all patients with
silent ischemia, the diffusion MRI findings were revealed
diffusion restriction due to distal thromboembolism, not
secondary to covered perforating arteries. Of 14 cases, 13
did not present any clinical sign of ischemia during the
follow-up period (range, 12–94 months). The aneurysms
were totally occluded in all cases. The related findings are
summarized in Table 3.
3.1. Periprocedural complications
No periprocedural major complication, such as rupture,
thromboembolism, subarachnoid hemorrhage, or
acute occlusion of covered arteries, was seen, except
one. Patient 14 (Table 3) had two aneurysms in the ICA
terminal segment and an MCA bifurcation aneurysm
(Figure 4a, 4b). Before the procedure, the A1 segment
of the contralateral ACA was hypoplasic (0.78 mm). The
proximal one was partially filled with three coils for the
ICA aneurysms. Then a 3.5 x 14 mm Pipeline Shield device
was implanted, extending from MCA to ICA and covering
both aneurysm necks. The MCA bifurcation aneurysm

Table 1. Localizations of aneurysms.
Localization

Number

ICA terminal segment (C7)

18

AChoA orifice

5

PcomA orifice

2

ICA: Internal carotid artery. AChoA: Anterior choroidal artery. PcomA: Posterior communicating artery.
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Table 2. Arteries covered with flow-diverting stents and their occlusion status in the last follow-up.
Number of covered arteries

Number of occlusions

ACA

14

2

AChoA

14

0

PcomA

2

1

Ophthalmic artery

9

2

ACA: Anterior cerebral artery. AChoA: Anterior choroidal artery. PcomA: Posterior communicating artery.

Figure 1. Schematic drawing of the relationship between the arterial structures
in the circle of Willis and flow-diverting stents. (*/**) *: Number of patients
defined to have patent arteries before the procedure. **: Number of patients
that developed occlusion after the procedure. ACA: Anterior cerebral artery.
AChoA: Anterior choroidal artery. PcomA: Posterior communicating artery.

Figure 2. a) 3D images show the existing aneurysms in the right ICA terminal
(curved arrow) and AChoA orifice (straight arrow). b) Postprocedural images
reveal the occluded ipsilateral ACA. c) Anterior circulation is compensated by
the increase in the diameter of the contralateral ACA. (ICA: Internal carotid
artery, ACA: Anterior cerebral artery, AChoA: Anterior choroidal artery).
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Figure 3. a) Preprocedural images of the aneurysms in the ICA terminal
segment (*) and AChoA orifice using flow diverting stents and additionally
a coil in the terminal segment. b) Remodeling images in which the aneurysm
in the AChoA orifice (*) is significantly reduced in size but remains patent
due to the perforating arteries originating from the neck (ICA: Internal
carotid artery. AChoA: Anterior choroidal artery).

was also treated with an FDS. In the images taken after
the procedure, a partial thrombus was detected in the
ipsilateral ACA A1 segment, the flow of which was not
completely blocked (Figure 4c). The thrombus persisted
despite administering a total of 1 mg IV tirofiban. After
contralateral femoral artery access, the contralateral
carotid injection was applied, and images were obtained.
The ACA A1 segment rapidly adapted to compensate for
this situation, increasing its diameter from 0.78 to 1.1
mm (Figure 4d, 4e). It was determined that there was no
problem in the blood supply to the ipsilateral ACA distal
segment after the contralateral carotid injection; thus, the
procedure was terminated. No complication, including
occult ischemia, was detected during the follow-up.
3.2. Long term complications
There was no long-term complication in 13 patients
(92.85%). In the single remaining case (7.14%), the 24thmonth-follow-up DSA showed 75% narrowing in the
proximal part of the FDS, which led to recurrent symptoms.
Therefore, a Wingspan stent (Stryker, Kalamazoo- MI)
was implanted. The follow-up examinations performed
after the second procedure revealed no sign of in-stent
thrombus, intimal hyperplasia, or clinical symptoms.
4. Discussion
Darsaut et al. conducted preclinical studies in 2012 and
2014 to evaluate FDSs in 21 and 17 experimental animals,
respectively. In both studies, stents with a different number
of wires were used in three variants of an aneurysm
model (straight sidewall, curved sidewall, and end-wall
bifurcation), and the FDSs were reported to be effective
in the treatment of straight sidewall aneurysms but not
incurved sidewall and end-wall bifurcation aneurysms
[15,16]. However, we consider that the data from these
studies could mislead readers with radical results obtained
over a short period of only 12 weeks. Contrary to the

implications of these preclinical studies, the efficacy and
safety of FDSs on aneurysm occlusion have been proven by
meta-analyses and case series in the literature [4–7,17,18].
Recent preclinical studies have attempted to explain
the diameter and flow modifications in the arteries covered
with FDSs. Iosif et al. conducted three studies on this
subject. They measured the changes in the irrigation areas
of the arteries covered with FDSs, as well as the alteration
in the flow of these arteries using computational fluid
dynamics. In addition to an optical coherence tomography
(OCT) examination before euthanasia, the authors
also performed an electron microscopic evaluation by
dissecting the covered arteries after euthanasia [12–14].
In these studies, it was described that the patency of the
arteries covered with FDS depended on the presence of an
alternative collateral network in the irrigation area of the
covered artery. There was also clinical research conducted
without evaluation of electron microscopy and OCT,
similarly indicating that symptomatic modifications in the
covered arteries after treatment with FDS were based on
the extent and type of collateral supply [19].
In light of large case series and meta-analyses,
treatment of intracranial aneurysms with FDSs is a
highly effective method in the occlusion of aneurysms
[4–7,17,18]. However, there are still concerns arising
from their denser metallic structure, higher surface
coverage, and lower porosity than conventional stents
used in intracranial aneurysm treatment [1], leading to
complications in the irrigation areas of the arteries when
applied. A case report was also available in the literature
to justify experts’ concerns concerning this issue [20].
Due to all these concerns, new literature data were
obtained in relation to the use of FDSs in cases that were
technically difficult or almost impossible to treat with
current treatment modalities. Until the last 5 years, studies
on FDSs mainly focused on whether aneurysms were
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Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Patient 8

Patient 9

Patient 10

Patient 11

Patient 13

Patient 14

2.15

2.5

2.7

2.4

2.3

2.1

1.73

1.5

2.2

0.9

1.85 2.07

0.85

2.6

ACA A1 diameter on the
an. side after procedure 1.06
(mm)

0.9

0

0

1.4

0.5

1.1

0.46

1.24

0.7

0.92 1.04

0.72

1.07

Contrateral ACA A1
diameter before the
procedure (mm)

0.8

1.4

2.2

2.1

1.6

1.3

2.12

1.6

1.6

1.7

2.06

2.26

0.78

Contrateral ACA A1
diameter after procedure 2
(mm)

1.4

1.5

2.76

2

2.28

1.82

2.3

1.93

1.76 1.92 2.05

2.21

1.07

PCA P1 diameter on
the an. side before
procedure (mm)

2.07

2

1.8

1.7

1.8

1.9

1.35

1.7

1.45

2.18 2.39 2.05

1.63

1.34

PCA P1 diameter on the
an. side after procedure 2.07
(mm)

2

1.8

1.8

1.8

2.21

1.64

1.7

1.45

2.15 2.25 2

1.5

1.33

OA diameter before
procedure (mm)

0.9

0.6

0.5

0.5

0.6

0.4

0.6

0.68

0.6

0.85 0.82 1.04

0.68

1.11

OA diameter after
procedure (mm)

0.9

0.9

0.5

0.6

0.6

0.4

0

0.6

0.6

0.83 0.9

0.95

0

1.11

PcomA diameter before
0
procedure (mm)

0

0.8

0

0

0

0

0

0

0

0

0

0

0.78

PcomA diameter after
procedure (mm)

0

0

0

0

0

0

0

0

0

0

0

0

0

0.8

Raymond-Roy
classification

TO

TO

TO

TO

TO

TO

TO

TO

TO

TO

TO

TO

TO

TO

Branches covered by
FDS*

1,2,3,4 1,4

1,2,3,4 1,2,4 1,2,3,4 1,2,3,4 1,2,3,4 1,2,3,4 1,2,3,4 1,2,4 1,2,4 1,2,3,4 1,2,3,4 1,2,4

3

1

3

1

2

1

2

1

3

1

1

3

1

2

-

-

-

+

-

-

+

+

-

+

-

-

+

+

1

2

3

4

3

3

4

3

3

6

2

2

5

5

1

1

1

1

1

1

2

1

1

1

1

3

1

1

ACA A1 diameter on
the an. side before
procedure (mm)

Number of an.
Presence of silent
infarction on MRI
on the first day after
procedure
Type of FDS**
Number of FDS/FDSs
use

1.74

Patient 12

Patient 1

Table 3. Diameter changes before and after flow-diverting stent implantation and evaluation of response to aneurysm treatment.

* 1: ACA (Anterior cerebral artery) 2: PcomA (Posterior communicating artery) 3: OA (Ophthalmic artery) 4: AChoA (AChoroidal
artery)
* *1: Pipeline flex 2: Silk 3: Derivo 4: Surpass 5: Pipeline Shield 6: DerivoII
An: Aneurysm. FDS: Flow diverting stent. PCA: Posterior cerebral artery. TO: Totally occluded.
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Figure 4. a,b) 3D and DSA images of the patient with two
aneurysms in the ICA terminal (*,**) and one aneurysm in MCA
bifurcation (***). c) Image obtained at the end of the procedure
revealing a thrombus (curved arrow) in the ipsilateral ACA A1
segment, which does not block the flow. d) DSA obtained with
contralateral carotid injection before the procedure. e) DSA
obtained with contralateral carotid injection after the procedure,
revealing increase in calibration after rapid modification in the
ACA A1 segment (ICA: Internal carotid artery. ACA: Anterior
cerebral artery. MCA: Middle cerebral artery).

occluded. But some meta-analyses [4–7,9,10,18,21] and
case series [8,11,19,22–24] that retrospectively compile
data from defined the complications of this treatment
modality and type of clinical problems it might cause. A
meta-analysis including IntrePED, PUFS, and ASPIRe
studies determined the major ipsilateral ischemic stroke
rate as 3.7%, major ipsilateral intracranial bleeding as
2.0%, major neurological morbidity rate as 5.7%, mortality
rate as 3.3%, and the combined rate of major neurological
morbidity and mortality as 7.1% [9]. In the IntrePED study,
it is found that acute ischemic stroke was associated with
male sex, hypertension, treatment of fusiform and/or giant

aneurysms, and use of multiple FDSs in the univariate
analysis and only fusiform treatment in the multivariate
analysis [10]. In our series, only one patient (Patient 4)
experienced late recurrent ischemic symptoms, which
reminded us of the importance of fusiform aneurysms
described by Brinjikji et al. [10] in ischemic stroke
(Table 3). The authors also stated that more catastrophic
complications might occur in posterior circulation
aneurysms compared to anterior circulation.
Studies have also investigated the specific patency of
individual arteries covered. To our knowledge, although
there are several studies on postprocedural modifications
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of the ophthalmic artery [25], PComA [26], and AChoA
[27,28], there are two studies in the literature presenting
data on all distal branches of the ICA [11, 29]. Recently,
a newer study was documented about outcomes of ACA
covered by FDSs [30]. Based on all these publications, the
number of studies published in the literature is insufficient
to evaluate the diameter and flow modifications in the
anterior circulation and clinical follow-up after using FDSs
to cover ACA. In a case series of 82 patients published by
Rangel-Castilla et al. [29], ACA was covered by an FDS
only in two cases. Both presented with asymptomatic
occlusion, which was found during the follow-up. In
the other case series, including 140 patients and 147
aneurysms reported by Bhogal et al., 14 patients had
ACA covered by FDS. Two of these patients developed
occlusion, and six had decreased flow [11]. A wider case
series included 42 patients who had ACA covered by FDS.
ACA narrowed or occluded in 35 of 42 patients [30].
However, the authors reported no symptoms during the
follow-up. They noted that the distal ACA A2 segment
in the patients with occlusion or narrowing was fed by
AComA in contralateral circulation [11,29, 30]. Our
study found decreased ipsilateral diameter and flow in
12 of 14 patients, and occlusion was present in two. DSA
performed by contralateral carotid injection revealed that
in the patients with occlusion, the ipsilateral ACA A1 and
A2 segments were filled with AComA. The contralateral
ACA A1 diameters of these patients increased, and it
was also noted that the flow was visually increased in
DSA images. Neurological deficits were not detected in
any of these patients during the follow-up. An ipsilateral
thrombus developed only in one case, described in the
section on periprocedural complications. This patient
could not be evaluated by a physical examination because
she was under general anesthesia. The synchronous MCA
bifurcation aneurysm of this patient was also treated in the
same session. First, the ICA terminal segment aneurysms
were treated with an FDS, and then the MCA aneurysm
was treated through the same access route. We consider
that this complication occurred because of the prolonged
catheterization time, leading to increased thrombogenicity
at the implantation site. A thrombus in the ipsilateral
ACA in this patient did not completely cut off the flow but
significantly decreased it. Upon observing no thrombus
resolution despite 1 mg of IV tirofiban administration,
DSA was undertaken with a contralateral carotid injection
to evaluate whether anterior circulation was affected. This
procedure showed that ipsilateral anterior circulation was
not affected due to the flow compensation.
AChoA was covered by an FDS in all 14 patients, but
no occlusion was detected in any of our cases, consistent
with previous reports [11,26–29]. Only in one case, in
which AChoA originated from the aneurysm neck, there
was a decrease in the AChoA flow. Neither a decrease in
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diameter nor a decrease in flow was detected in any of our
remaining patients. Furthermore, no patient presented with
a neurological symptom, physical examination finding, or
diffusion MRI sign suggesting ischemia in ganglionic and
capsular localizations fed by AChoA. We consider that the
acute ganglionic infarction described in a case report by
Rooij and Sluzewski in 2010 was probably due to the use
of two FDSs and technical complications related to the
procedure [20]. Previous meta-analyses also associated such
complications with the use of multiple FDSs in the univariate
analysis, which can also explain the situation described by
Rooij and Sluzewski [10].
The ophthalmic artery was covered by an FDS in nine
of our cases, of which two were observed to have occlusion
on the follow-up DSA. The diameter changes in this artery
were statistically analyzed, and the reduction in diameter
was not statistically significant. No ophthalmologic symptom
was found in any of these patients, which can be explained
by the presence of collateral support, probably provided by
the external carotid artery. This finding was consistent with
the data reported in the literature [11,25,26]. However, in
their detailed ophthalmologic examination, Rouchaud
et al. found a very high rate of optic atrophy and retinal
artery thromboembolism, which were observed to progress
subclinically [22]. The findings described by Rouchaud et
al. could not be verified because a detailed ophthalmologic
examination was not performed in our study.
Before the procedure, two of the 14 patients had ipsilateral
PComA patency in this study. The PComA was covered with
an FDS in both patients, and occlusion was observed in one
patient after the procedure; however, there was no clinical
sign of ischemia.
In our analyses, no statistically significant increase was
found in the measurement of the mean diameter of the
ipsilateral posterior cerebral artery P1 segment. However, we
consider it inappropriate to generalize this finding since only
two of our patients had nonfetal type PComA.
On the first day after the procedure, foci compatible
with silent ischemia were found in diffusion-weighted MRI
of six patients, but no additional medication was required.
We evaluated the relationship of this parameter with the
number of FDSs used. A single FDS was used in five of the
six patients with diffusion restriction (83.3%) and two FDSs
in the remaining patient (16.7%). Contrary to previous
studies in the literature indicating a correlation between
the number of FDS and the rate of clinically detected
ischemia, the chi-square analysis of our data did not reveal
a statistically significant correlation between silent ischemia
and the number of FDS. However, due to the small sample
size in our study and the fact that despite the absence of
clinical symptoms in our patients, we investigated silent
ischemia in more detail than in other studies, we consider
that our statistical analysis results are not correlated with the
literature. In the long-term, no neurological morbidity or
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mortality was detected during the clinical (12–94 months)
or radiological (6–94 months) follow-up based on DSA in
any of our patients.
4.1. Study limitations
The main limitations of this study were the number of
cases and retrospective. Other limitations included the
absence of an OCT examination, the gold standard for
evaluating covered arteries in animal studies, the inability
to analyze computational fluid dynamics [31], and the lack
of a detailed ophthalmologic examination. Additionally,
the DSA of the selective external carotid and vertebral
arteries, which would allow collateral networks to be more
clearly demonstrated, was not obtained for all patients.
5. Conclusion
Since the sample size is small, it is not possible to make
generalizations based on our data; however, we observed

structural changes in the circle of Willis, especially ACA,
following the use of FDSs extending from MCA to ICA. If
AComA is patent, anterior circulation can be compensated
through the modifications in the contralateral ACA A1
segment. Thus, this effective treatment can be applied
more safely.
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